NorUDCA Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving NorUDCA Growth

• Strong Phase III efficacy data in an area of major unmet need

In May 2025, Dr. Falk Pharma announced positive topline results from the pivotal Phase III NUC-5 trial involving 301 PSC patients. NorUDCA demonstrated statistically significant superiority over placebo on the composite primary endpoint, including partial normalization of alkaline phosphatase (ALP) and no histological disease worsening after 96 weeks. Approximately 15.1% of NorUDCA-treated patients achieved the primary endpoint versus 4.2% on placebo (p=0.0048). Histologic improvement was also significantly higher with NorUDCA. These data substantially de-risk the asset and strengthen its regulatory and commercial outlook.

• Absence of approved therapies for PSC creates first-mover advantage

PSC remains one of the few chronic cholestatic liver diseases without an approved drug therapy in the US or EU. Current management relies largely on liver transplantation and off-label use of Ursodeoxycholic acid. Because NorUDCA may become the first approved therapy specifically for PSC, it could rapidly establish strong physician adoption and premium orphan-drug pricing. The rarity and severity of PSC also support accelerated regulatory review pathways and favorable reimbursement dynamics.

• Unique mechanism of action differentiates NorUDCA from conventional UDCA

NorUDCA is a side-chain shortened derivative of UDCA with distinct pharmacologic properties. Unlike conventional UDCA, NorUDCA undergoes “cholehepatic shunting,” generating bicarbonate-rich hypercholeresis and direct cholangioprotective effects. Preclinical and clinical studies suggest it may reduce cholestatic injury, inflammation, and fibrosis progression more effectively than standard bile acid therapies. This differentiated mechanism enhances its positioning versus symptomatic or anti-inflammatory competitors in PSC development pipelines.

• Orphan drug incentives support long-term commercial potential

NorUDCA received orphan drug designation from the European Medicines Agency for PSC in 2014. Orphan designation provides benefits including market exclusivity, regulatory support, and fee reductions, all of which improve commercial attractiveness for rare liver diseases. PSC prevalence is estimated below 5 per 10,000 population in Europe, supporting premium pricing potential and limited direct competition.

• Growing awareness and diagnosis of PSC expands addressable patient pool

Increasing use of MRCP imaging, improved hepatology referral patterns, and rising awareness of autoimmune liver diseases are leading to earlier and more frequent PSC diagnoses. Industry and academic estimates generally place PSC prevalence at roughly 30,000-50,000 patients across the US and Europe combined. Given the chronic progressive nature of PSC, long treatment duration could support sustained recurring revenue if NorUDCA gains approval.

• Potential blockbuster opportunity despite orphan indication

Although Dr. Falk Pharma is privately held and has not publicly disclosed sales forecasts, several analysts and industry observers have suggested that effective PSC therapies could achieve blockbuster-level annual sales due to the lack of competition and high unmet need. Recent investor commentary around PSC therapeutics has referenced “$1B+ commercial opportunities” for successful entrants in the PSC market. If NorUDCA secures approvals in major markets by 2027-2028, peak annual sales could potentially approach or exceed US$500 million-US$1 billion globally, depending on pricing, label breadth, and market penetration.

NorUDCA Recent Developments

In August 2025, In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) secured the world's first regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD.  
“NorUDCA Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of NorUDCA for potential indication like Primary sclerosing cholangitis, Non-alcoholic steatohepatitis, and Primary biliary cirrhosis in the 7MM. A detailed picture of NorUDCA’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the NorUDCA for potential indications. The NorUDCA market report provides insights about NorUDCA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current NorUDCA performance, future market assessments inclusive of the NorUDCA market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of NorUDCA sales forecasts, along with factors driving its market.

NorUDCA Drug Summary

NorUDCA (norursodeoxycholic acid; also referred to as norucholic acid) is a novel, side-chain-shortened derivative of ursodeoxycholic acid (UDCA) being developed for the treatment of cholestatic and metabolic liver diseases, including primary sclerosing cholangitis (PSC), nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated fatty liver disease (MAFLD), and nonalcoholic steatohepatitis (NASH). Unlike conventional UDCA, NorUDCA is relatively resistant to glycine and taurine conjugation, enabling a unique process called cholehepatic shunting, which enhances bicarbonate-rich bile flow (hypercholeresis) and exerts potent anti-inflammatory, antifibrotic, anticholestatic, and hepatoprotective effects. Preclinical and clinical studies have demonstrated its ability to reduce liver fibrosis, improve liver enzyme levels, decrease hepatic fat accumulation, and protect cholangiocytes from bile acid-induced injury. Clinical development has been led by Dr. Falk Pharma and regional partners such as EA Pharma and Shilpa Medicare, with multiple Phase II and Phase III studies reporting favorable efficacy and safety outcomes in liver disorders. The report provides NorUDCA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the NorUDCA Market Report

The report provides insights into:

• A comprehensive product overview including the NorUDCA MoA, description, dosage and administration, research and development activities in potential indication like Primary sclerosing cholangitis, Non-alcoholic steatohepatitis, and Primary biliary cirrhosis.
• Elaborated details on NorUDCA regulatory milestones and other development activities have been provided in NorUDCA market report.
• The report also highlights NorUDCA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The NorUDCA market report also covers the patents information, generic entry and impact on cost cut.
• The NorUDCA market report contains current and forecasted NorUDCA sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The NorUDCA market report also features the SWOT analysis with analyst views for NorUDCA in potential indications.

Methodology

The NorUDCA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NorUDCA Analytical Perspective

• In-depth NorUDCA Market Assessment

This NorUDCA sales market forecast report provides a detailed market assessment of NorUDCA for potential indication like Primary sclerosing cholangitis, Non-alcoholic steatohepatitis, and Primary biliary cirrhosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted NorUDCA sales data uptil 2034.

• NorUDCA Clinical Assessment

The NorUDCA market report provides the clinical trials information of NorUDCA for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

NorUDCA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

NorUDCA Market Potential & Revenue Forecast

• Projected market size for the NorUDCA and its key indications
• Estimated NorUDCA sales potential (NorUDCA peak sales forecasts)
• NorUDCA Pricing strategies and reimbursement landscape

NorUDCA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• NorUDCA Market positioning compared to existing treatments
• NorUDCA Strengths & weaknesses relative to competitors

NorUDCA Regulatory & Commercial Milestones

• NorUDCA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

NorUDCA Clinical Differentiation

• NorUDCA Efficacy & safety advantages over existing drugs
• NorUDCA Unique selling points

NorUDCA Market Report Highlights

• In the coming years, the NorUDCA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The NorUDCA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NorUDCA’s dominance.
• Other emerging products for Primary sclerosing cholangitis, Non-alcoholic steatohepatitis, and Primary biliary cirrhosis are expected to give tough market competition to NorUDCA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NorUDCA in potential indications.
• Analyse NorUDCA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted NorUDCA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of NorUDCA in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of NorUDCA? How strong is NorUDCA’s clinical and commercial performance?
• What is NorUDCA’s clinical trial status in each individual indications such as Primary sclerosing cholangitis, Non-alcoholic steatohepatitis, and Primary biliary cirrhosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NorUDCA Manufacturers?
• What are the key designations that have been granted to NorUDCA for potential indications? How are they going to impact NorUDCA’s penetration in various geographies?
• What is the current and forecasted NorUDCA market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of NorUDCA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to NorUDCA for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is NorUDCA? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.